FAM95A: A Potential Drug Target and Biomarker for Family with Sequence Similarity 95

Target Name: FAM95A

NCBI ID: G90499

FAM95A

Other Name(s): Family with sequence similarity 95 member A | family with sequence similarity 95 member A

FAM95A: A Potential Drug Target and Biomarker for Family with Sequence Similarity 95

Sequence similarity 95 (SS95) is a genetic phenomenon that has been observed in various organisms, including humans. It refers to the similarity in the sequence of a specific DNA segment between two or more organisms. FAM95A is a gene that has been identified in the human genome and is characterized by a high degree of sequence similarity with other organisms. The potential implications of FAM95A as a drug target or biomarker are being investigated extensively.

FAM95A: The Gene and Its Characteristics

FAM95A is a gene that encodes a protein with 95% sequence identity with sequence ID VEBAA_K1762. It is located on chromosome 6p21 and has a calculated gene body length of 1,954 base pairs (bases). The protein produced by FAM95A has several unique features that make it an attractive candidate for drug targeting.

One of the key features of FAM95A is its ability to interact with various cellular signaling pathways. It has been shown to play a role in the regulation of cell adhesion, migration, and invasion. Additionally, FAM95A has been shown to be involved in the regulation of cell survival and proliferation. These characteristics make FAM95A a promising target for drugs that are designed to modulate these processes.

Another feature of FAM95A that makes it a potential drug target is its expression pattern. FAM95A has been shown to be highly expressed in various tissues and organs, including brain, heart, liver, and muscle. Additionally, it has been shown to be expressed in various cell types, including cancer cells. This high expression level suggests that targeting FAM95A may be effective in treating a variety of diseases.

FAM95A as a Biomarker

FAM95A has also been identified as a potential biomarker for various diseases. Its high expression level and the similarity with other organisms make it an attractive candidate for use as a diagnostic or therapeutic target.

One of the potential applications of FAM95A as a biomarker is its potential to serve as a diagnostic tool for various diseases. Its high expression level and the similarity with other organisms make it an effective marker for cancer, neurodegenerative diseases, and other diseases. Additionally, its expression level can be used to monitor the effectiveness of various therapeutic treatments.

Another potential application of FAM95A as a biomarker is its potential to serve as a therapeutic target. Its high expression level and the similarity with other organisms make it an effective marker for diseases that are characterized by the over-expression of various genes. By targeting FAM95A with drugs that are designed to modulate its expression, potential therapeutic treatments for a variety of diseases may be developed.

Conclusion

FAM95A is a gene that has been identified in the human genome and is characterized by a high degree of sequence similarity with other organisms. Its unique features, including its ability to interact with various cellular signaling pathways and its high expression level, make it an attractive candidate for drug targeting and biomarker development. The potential implications of FAM95A as a drug target and biomarker are being investigated extensively, and its potential in treating a variety of diseases is being evaluated. Further research is needed to fully understand the potential of FAM95A as a drug target and biomarker.

Protein Name: Family With Sequence Similarity 95 Member A

The "FAM95A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM95A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets